COMPARISON
Lanreotide vs Octreotide
6 attributes held for at least one of the two. 6 differ. Each value carries the register it came from and the date that register was read.
Answer
Lanreotide is authorised or registered in 9 and Octreotide in 10 of the 10 registers read. Lanreotide: highest phase Phase 4 (after approval). Octreotide: highest phase Phase 4 (after approval). 40 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Lanreotide | Octreotide | |
|---|---|---|
| Registered trials differs | 125 clinicaltrials.gov · 2026-10-03 | 344 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Lanreotide Acetate openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Octreotide Acetate openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Nothing on record ema read 2026-08-31 | Authorised ema · 2026-10-03 |
| EU authorised on differs | Not checked no record of "authorisedOn" for lanreotide | 2025-06-30 ema · 2026-10-03 |
| EU withdrawn on differs | Not checked no record of "withdrawnOn" for lanreotide | 2022-12-02 ema · 2026-10-03 |
| ATC code differs | Not checked no record of "atcCode" for lanreotide | H01CB02 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Lanreotide | placebo | Octreotide | placebo |
|---|---|---|---|---|
| Diarrhoea | 19.5% | 23.6% | 46.2% | 31.7% |
| Fatigue | 12.2% | 14.6% | 29.8% | 27.7% |
| Nausea | 11.0% | 12.0% | 30.8% | 21.2% |
| Hypertension | 8.8% | 5.6% | 26.5% | 19.4% |
| Decreased appetite | 8.0% | 8.6% | 28.5% | 15.2% |
| Abdominal pain | 16.8% | 15.9% | - | - |
| Vomiting | 10.8% | 7.8% | - | - |
| Headache | 10.7% | 9.4% | - | - |
| Arthralgia | 8.0% | 8.2% | - | - |
| Back pain | 8.0% | 10.3% | - | - |
| Oedema peripheral | - | - | 34.9% | 19.6% |
| Asthenia | - | - | 33.3% | 20.9% |
| Rash | - | - | 28.8% | 14.1% |
| Dyspnoea | - | - | 25.9% | 9.1% |
| Anaemia | - | - | 24.3% | 9.1% |
Trial register Lanreotide: 5 placebo-controlled trials; Octreotide: 5. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Lanreotide side effects · Octreotide side effects
LEGAL STATUS
Approval in each country read
| Country | Lanreotide | Octreotide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Not on the register | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
40 registered trials include both
| 2024-516616-24-00 | A Phase 3 randomized 3-arm trial (double-blind Debio 4126, placebo control, and open-label Debio 4126), to assess the efficacy and safety of Debio 4126, a 12-we Not stated · updated 2026-09-23 |
|---|---|
| NCT06878664 | Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors RECRUITING · updated 2026-09-16 |
| 2023-509334-19-00 | Trial title: Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inop Not stated · updated 2026-08-31 |
| 2023-508723-12-00 | A randomized, multi-center, open-label, active-controlled Phase 3 trial to assess the efficacy and safety of octreotide subcutaneous depot (CAM2029) versus octr Not stated · updated 2026-08-10 |
| NCT07087054 | Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen RECRUITING · updated 2026-08-04 |
| NCT05050942 | A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET ACTIVE_NOT_RECRUITING · updated 2026-07-28 |
| 2023-505884-35-00 | Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with long-acting Somatostatin Analogues – ATSA trial Not stated · updated 2026-06-17 |
| NCT07534371 | Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study ACTIVE_NOT_RECRUITING · updated 2026-04-16 |
| NCT05477576 | Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy RECRUITING · updated 2026-03-30 |
| NCT05361668 | Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome COMPLETED · updated 2026-03-19 |
| 2025-521243-20-00 | A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose Range-finding, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALXN2 Not stated · updated 2026-01-08 |
| NCT05364944 | A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropanc TERMINATED · updated 2025-11-17 |
| 2022-502703-30-00 | Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumour pAtients (SAUNA trial) Not stated · updated 2025-09-24 |
| NCT03289741 | A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide COMPLETED · updated 2025-05-09 |
| NCT03792555 | A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve) COMPLETED · updated 2025-03-17 |
| NCT02795858 | A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors COMPLETED · updated 2025-02-19 |
| NCT02736448 | 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors TERMINATED · updated 2025-01-13 |
| NCT05701241 | Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients RECRUITING · updated 2024-06-14 |
| NCT01070758 | Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy COMPLETED · updated 2024-04-18 |
| NCT03967249 | Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands COMPLETED · updated 2023-03-22 |
The 20 most recently updated are listed.
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.